secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001493152-24-041886
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus partners with BeiGene to test Decoy20 + tislelizumab combo in solid tumors
--------------------------------------------------------------------------------

- Clinical supply agreement with BeiGene Switzerland GmbH for anti-PD-1 antibody tislelizumab.
- Indaptus funds all study costs except BeiGene's product; BeiGene supplies tislelizumab.
- Plans to seek FDA approval and begin combination study in 2025 for advanced solid tumors.
- Decoy20 is Indaptus' novel immune-response-inducing candidate for cancer therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224041886/0001493152-24-041886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224041886/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-041886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer